SETD2 Inhibitors

The chemical class known as SETD2 Inhibitors comprises a range of compounds that interact with the SETD2 protein or its associated cellular pathways to modulate its activity. These inhibitors typically do not directly bind to the SETD2 active site. Instead, they may compete with the natural substrate of SETD2, such as S-Adenosylmethionine (SAM) analogs, or might decrease the availability of the methyl donor pool as seen with 5'-Deoxy-5'-(methylthio)adenosine. Others, like Methylthioadenosine (MTA), are byproducts of cellular metabolism that can influence methylation reactions broadly, potentially affecting SETD2's function.

Compounds such as 3-Deazaneplanocin A (DZNep) act by inhibiting enzymes like S-adenosylhomocysteine hydrolase, which results in the accumulation of S-adenosylhomocysteine (SAH), a natural inhibitor of methyltransferases including SETD2. Other inhibitors could affect SETD2 indirectly by altering the epigenetic landscape of the cell, such as Nicotinamide, which inhibits sirtuin enzymes and thereby can change histone methylation patterns. Similarly, DNA methyltransferase inhibitors like Decitabine and RG108 could impact the chromatin state and modulate SETD2 activity. Kinase inhibitors such as 2,4-Dichloro-1H-pyrazolo[3,4-d]pyrimidine could disrupt signaling pathways that influence SETD2's role in chromatin remodeling and gene expression.